Leishmaniasis
SAUDI ARABIA

Country General Information (WHO, 2013)

Total population: 28,829,000
Gender (%: 42.5% / 57.5%
GDP (PPP int $): 53,780
Income status: High

Epidemiology

Number of new cases (incidence): 28,829,000
Number of relapse cases: 2
Total number of cases: 17
Imported cases (%): 17%
Age group distribution (%): 12 / 15 / 71
Incidence rate at the national level: 0.01
Number of endemic second sub-national administrative level divisions (n): 5
Number of new foci: 17
Was there any outbreak? No

Number of new CL cases reported by month in 2013 and 2014

Number of new (primary) VL cases reported by month in 2013 and 2014

Number of cases and incidence rate of CL

Number of cases and incidence rate of VL

1 Defined as "Number of people living in 1st sub-national administrative level endemic areas"
2 For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever
3 Incidence rate at the national level

Published in July 2016

Country General Information (WHO, 2013)

Total population: 28,829,000
Age group <15>14 years, %: 29% / 71%
Gender (%: 42.5% / 57.5%
GDP (PPP int $): 53,780
Income status: High

Epidemiology

Number of new cases (incidence): 28,829,000
Number of relapse cases: 2
Total number of cases: 17
Imported cases (%): 17%
Age group distribution (%): 12 / 15 / 71
Incidence rate at the national level: 0.01
Number of endemic second sub-national administrative level divisions (n): 5
Number of new foci: 17
Was there any outbreak? No

Number of new CL cases reported by month in 2013 and 2014

Number of new (primary) VL cases reported by month in 2013 and 2014

Number of cases and incidence rate of CL

Number of cases and incidence rate of VL

1 Defined as "Number of people living in 1st sub-national administrative level endemic areas"
2 For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever
3 Incidence rate at the national level

Published in July 2016
Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established: 1983
Year latest national guidelines were published: 2000
Type of surveillance: Integrated
Is leishmaniasis a notifiable disease (mandatory reporting)? Yes
Is there a vector control programme? Yes
Is there a reservoir host control programme? No
Type of insecticide used for IRS: Deltamethrin
Number of leishmaniasis health facilities: 249

Diagnosis

<table>
<thead>
<tr>
<th></th>
<th>VL</th>
<th>ACL</th>
<th>ZCL</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of people screened actively for:</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>Number of people screened passively for:</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>VL cases diagnosed by RDT* (%):</td>
<td>100% (11 / 12)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of positive RDT* (%):</td>
<td>No data</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Cases diagnosed by direct exam (parasitology) (%):</td>
<td>0% (0 / 12)</td>
<td>No data</td>
<td>No data</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of positive slides (%):</td>
<td>No data</td>
<td>(0 / 0)</td>
<td>No data</td>
<td>N/A</td>
</tr>
<tr>
<td>Cases diagnosed clinically (%):</td>
<td>0% (0 / 12)</td>
<td>No data</td>
<td>No data</td>
<td>N/A</td>
</tr>
<tr>
<td>Percentage of cases with HIV-VL coinfection:</td>
<td>0% (0 / 12)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* These indicators apply only for new (primary) VL cases

Treatment and medicines

Is treatment provided free of charge in the public sector? Yes

Antileishmanial medicines included in the national List of Essential Medicines: Sodium stibogluconate (SSG), Liposomal amphotericin B

TREATMENT OUTCOME

<table>
<thead>
<tr>
<th></th>
<th>VL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of relapse cases*</td>
<td>8% (1 / 12)</td>
</tr>
<tr>
<td>Initial cure rate:</td>
<td>92% (11 / 12)</td>
</tr>
<tr>
<td>Failure* rate:</td>
<td>0% (0 / 12)</td>
</tr>
<tr>
<td>Case-fatality rate:</td>
<td>0% (0 / 12)</td>
</tr>
</tbody>
</table>

* A relapse case in this country is defined as: Reappearance of lesion(s) after cure
* A failure case in this country is defined as: Deterioration or no improvement during the treatment period

Data source: Ministry of Health, Saudi Arabia © WHO 2014. All rights reserved.